IO Biotech, Inc.
IOBTDelisted Jun 8, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001865494
IO Biotech, Inc. was delisted on Jun 8, 2026; its insiders filed their last Form 4 on Jun 6, 2025; 12 institutions reported holding it in 13F filings for Q1 2026, worth $199.0K in total; no superinvestor held it.
13F holders, Q1 2022
Institutional positions in IO Biotech, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- −1 vs. Q4 2021
- Shares held
- 14.9M
- −179.6K (−1.2%) vs. Q4 2021
- Total value
- $76.9M
- −$15.7M (−17.0%) vs. Q4 2021
- New holders
- 4
- 2 more added
- Sold out
- 5
- 2 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IOBT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 12 | $199.0K |
| Q4 2025 | 22 | $4.78M |
| Q3 2025 | 21 | $3.59M |
| Q2 2025 | 26 | $25.3M |
| Q1 2025 | 22 | $20.8M |
| Q4 2024 | 27 | $18.2M |
| Q3 2024 | 20 | $24.8M |
| Q2 2024 | 20 | $30.7M |
| Q1 2024 | 18 | $47.4M |
| Q4 2023 | 18 | $55.3M |
| Q3 2023 | 19 | $41.7M |
| Q2 2023 | 15 | $24.0M |
| Q1 2023 | 17 | $26.1M |
| Q4 2022 | 17 | $32.8M |
| Q3 2022 | 21 | $41.6M |
| Q2 2022 | 18 | $72.2M |
| Q1 2022 | 19 | $76.9M |
| Q4 2021 | 20 | $92.6M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding IO Biotech, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Novo Holdings A/S | 3,277,932 | $17.4M | 0.92% | 00.0% | Unchanged |
| Vivo Capital, LLC | 3,015,545 | $16.0M | 1.10% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 1,857,755 | $9.85M | 0.21% | 00.0% | Unchanged |
| Avoro Capital Advisors LLC | 2,055,883 | $9.58M | 0.17% | 00.0% | Unchanged |
| PFM Health Sciences, LP | 1,362,144 | $6.65M | 0.26% | 00.0% | Unchanged |
| Capital World Investors | 1,235,000 | $6.55M | 0.00% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 1,120,437 | $5.94M | 1.50% | 00.0% | Unchanged |
| Soleus Capital Management, L.P. | 672,734 | $3.56M | 0.55% | 00.0% | Unchanged |
| Millennium Management LLC | 72,728 | $385.0K | 0.00% | −5,235−6.7% | Reduced |
| Vanguard Group Inc | 62,234 | $330.0K | 0.00% | −142,966−69.7% | Reduced |
| Susquehanna International Group, LLP | 26,676 | $141.0K | 0.00% | +26,676 | New |
| Norges Bank | 25,000 | $132.5K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 16,487 | $87.0K | 0.00% | +7,529+84.0% | Added |
| Jane Street Group, LLC | 14,280 | $76.0K | 0.00% | +14,280 | New |
| Geode Capital Management, LLC | 12,730 | $67.0K | 0.00% | +1,557+13.9% | Added |
| Ergoteles LLC | 11,126 | $59.0K | 0.00% | +11,126 | New |
| Bank of America Corp | 10,000 | $53.0K | 0.00% | 00.0% | Unchanged |
| Stifel Financial Corp | 10,000 | $53.0K | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 164 | $1.00K | 0.00% | +164 | New |
| Caas Capital Management LP | 0 | $0 | 0.00% | −50,479−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −14,966−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −13,060−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −12,665−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −1,572−100.0% | Sold out |